Related Experiment Videos
Neonatal candidiasis: prophylaxis and treatment
Kenneth F Tiffany1, Phillip B Smith, Daniel K Benjamin
1Duke University, Department of Pediatrics, Durham, NC, USA.
Expert Opinion on Pharmacotherapy
|August 10, 2005
Summary
Neonatal candidiasis is increasing in intensive care units, with a 20% mortality rate. Current treatment guidelines are lacking due to insufficient large-scale trials, impacting infant care.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Critical Care
Background:
- Rising incidence of invasive candidiasis in neonatal intensive care units (NICUs).
- Increased survival of extremely preterm neonates contributes to higher risk.
- Significant mortality rate (20%) associated with neonatal candidiasis.
Purpose of the Study:
- To highlight the challenges in managing neonatal candidiasis.
- To underscore the need for evidence-based guidelines for prophylaxis and treatment.
- To address the current therapeutic landscape for invasive fungal infections in neonates.
Main Methods:
- Review of existing multi-centre studies on neonatal candidiasis.
- Analysis of current prophylaxis recommendations and treatment practices.
- Identification of gaps in clinical trial data.
Main Results:
- Lack of large, multi-centre, randomised controlled trials hinders definitive guidance.
- Systemic prophylaxis is not currently recommended for neonatal populations.
- Amphotericin B deoxycholate remains the first-line treatment for invasive candidiasis.
Conclusions:
- Urgent need for robust clinical trials to establish optimal prophylaxis and treatment strategies.
- Current management relies on limited evidence, posing risks to vulnerable neonates.
- Further research is critical to improve outcomes for infants with invasive fungal infections.